Sermorelin is one of the few peptides that moved from mainstream endocrinology into the modern optimization space, and in this episode Ashishpal Singh, PA‑C and founder of Mool Med, explains why that matters by unpacking its FDA history, mechanisms as a GHRH analogue (not GH), and the commercial reasons it left retail pharmacies. He dives into how sermorelin can support pulsatile, sleep‑linked growth hormone, and where it fits clinically: TRT/HRT patients with blunted recovery, GLP‑1 users who want to lose fat while preserving muscle, perimenopausal women with early sarcopenia, and athletes rehabbing injuries. Listeners come away with a clear, no‑hype framework for when sermorelin is useful, when it isn’t, and how to use it intelligently alongside sleep, light, training, and foundational hormones

Chapters

00:00 Introduction to sermorelin and its history

00:28 Why understanding peptides like sermorelin matters

01:25 The research background and FDA approval of sermorelin

02:19 How sermorelin stimulates the pituitary to release growth hormone

03:13 Differences between sermorelin and direct growth hormone therapy

05:36 The FDA story and clinical use in pediatrics

07:01 Comparison of sermorelin with other growth hormone secretagogues

08:55 Who benefits from sermorelin: candidates and applications

11:03 Sermorelin for muscle maintenance, aging, and injury recovery

12:49 Using sermorelin with GLP-1 therapies and metabolic health

16:10 Special considerations for perimenopausal women and sarcopenia

17:07 Dosing, safety, and sourcing of sermorelin

18:58 Integrating sermorelin into a holistic health protocol

21:45 Final thoughts: safety, sourcing, and responsible use